About Proximagen
Proximagen is a company based in London (United Kingdom) founded in 2004 by Peter Jenner was acquired by Upsher-Smith in June 2012. Proximagen has raised $96.5 million across 2 funding rounds from investors including Lundbeck and Upsher-Smith. Proximagen has completed 1 acquisition, including Minster Pharmaceuticals. Proximagen operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter London, United Kingdom
- Founders Peter Jenner
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proximagen Group Limited
-
Annual Revenue
$164 (USD)-71as on Dec 31, 2016
-
Net Profit
$28.47 (USD)-60as on Dec 31, 2016
-
EBITDA
Not available
-
Total Equity Funding
$96.5 M (USD)
in 2 rounds
-
Latest Funding Round
$16 M (USD), Private Equity Round
Sep 29, 2011
-
Investors
Lundbeck
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Upsher-Smith
(Jun 13, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Proximagen
Proximagen has successfully raised a total of $96.5M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $16 million completed in September 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Proximagen
Proximagen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lundbeck and Upsher-Smith.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for CNS disorders are developed and advanced.
|
Locked | Locked | Locked | |
|
Manufacturer of generic drugs
|
Locked | Locked | Locked |
Investor details for Proximagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Proximagen
Proximagen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Minster Pharmaceuticals.
Investment portfolio details for Proximagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for CNS disorders including migraine were developed.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Proximagen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Proximagen
Detailed financials for Proximagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proximagen Comparisons
Peer comparison for Proximagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Proximagen
Proximagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of Proximagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proximagen
Complete news archive for Proximagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proximagen
Proximagen was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Proximagen is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Kenneth Mulvany is the current CEO of Proximagen.
Proximagen is a funded company, having raised a total of $96.5M across 2 funding rounds to date.
Annual revenue of Proximagen is $164 as on Dec 31, 2016.
Proximagen was founded in 2004 in London, United Kingdom, as a neuroscience research company. Drug development efforts are centered on neurodegenerative disorders such as Parkinsons disease and Alzheimers disease. Compounds are designed to target acetylcholine and dopamine receptors. Operations include research and preclinical activities in the biotechnology sector. The company was acquired by Upsher-Smith Laboratories in 2012.
Proximagen's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Proximagen has made 1 acquisition, including Minster Pharmaceuticals.
Proximagen has 2 investors. Key investors include Lundbeck, and Upsher-Smith.